A citation-based method for searching scientific literature

Yves Pommier, Mark J O'Connor, Johann de Bono. Sci Transl Med 2016
Times Cited: 300







List of co-cited articles
1135 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Rad52 prevents excessive replication fork reversal and protects from nascent strand degradation.
Eva Malacaria, Giusj Monia Pugliese, Masayoshi Honda, Veronica Marabitti, Francesca Antonella Aiello, Maria Spies, Annapaola Franchitto, Pietro Pichierri. Nat Commun 2019
39
12

Homology-Directed Repair and the Role of BRCA1, BRCA2, and Related Proteins in Genome Integrity and Cancer.
Chun-Chin Chen, Weiran Feng, Pei Xin Lim, Elizabeth M Kass, Maria Jasin. Annu Rev Cancer Biol 2018
103
5

Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.
Jonathan Ledermann, Philipp Harter, Charlie Gourley, Michael Friedlander, Ignace Vergote, Gordon Rustin, Clare L Scott, Werner Meier, Ronnie Shapira-Frommer, Tamar Safra,[...]. Lancet Oncol 2014
875
5

Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma.
Olga Kondrashova, Minh Nguyen, Kristy Shield-Artin, Anna V Tinker, Nelson N H Teng, Maria I Harrell, Michael J Kuiper, Gwo-Yaw Ho, Holly Barker, Maria Jasin,[...]. Cancer Discov 2017
151
5

Prediction of DNA Repair Inhibitor Response in Short-Term Patient-Derived Ovarian Cancer Organoids.
Sarah J Hill, Brennan Decker, Emma A Roberts, Neil S Horowitz, Michael G Muto, Michael J Worley, Colleen M Feltmate, Marisa R Nucci, Elizabeth M Swisher, Huy Nguyen,[...]. Cancer Discov 2018
132
5

Replication fork reversal triggers fork degradation in BRCA2-defective cells.
Sofija Mijic, Ralph Zellweger, Nagaraja Chappidi, Matteo Berti, Kurt Jacobs, Karun Mutreja, Sebastian Ursich, Arnab Ray Chaudhuri, Andre Nussenzweig, Pavel Janscak,[...]. Nat Commun 2017
159
5

MRE11 and EXO1 nucleases degrade reversed forks and elicit MUS81-dependent fork rescue in BRCA2-deficient cells.
Delphine Lemaçon, Jessica Jackson, Annabel Quinet, Joshua R Brickner, Shan Li, Stephanie Yazinski, Zhongsheng You, Grzegorz Ira, Lee Zou, Nima Mosammaparast,[...]. Nat Commun 2017
167
5


53BP1 regulates DSB repair using Rif1 to control 5' end resection.
Michal Zimmermann, Francisca Lottersberger, Sara B Buonomo, Agnel Sfeir, Titia de Lange. Science 2013
388
5

Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial.
Mansoor Raza Mirza, Elisabeth Åvall Lundqvist, Michael J Birrer, Rene dePont Christensen, Gitte-Bettina Nyvang, Susanne Malander, Maarit Anttila, Theresa L Werner, Bente Lund, Gabriel Lindahl,[...]. Lancet Oncol 2019
76
6

Rif1 prevents resection of DNA breaks and promotes immunoglobulin class switching.
Michela Di Virgilio, Elsa Callen, Arito Yamane, Wenzhu Zhang, Mila Jankovic, Alexander D Gitlin, Niklas Feldhahn, Wolfgang Resch, Thiago Y Oliveira, Brian T Chait,[...]. Science 2013
274
5

A chromatin localization screen reveals poly (ADP ribose)-regulated recruitment of the repressive polycomb and NuRD complexes to sites of DNA damage.
Danny M Chou, Britt Adamson, Noah E Dephoure, Xu Tan, Amanda C Nottke, Kristen E Hurov, Steven P Gygi, Monica P Colaiácovo, Stephen J Elledge. Proc Natl Acad Sci U S A 2010
376
5

Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.
Daniel D Von Hoff, Thomas Ervin, Francis P Arena, E Gabriela Chiorean, Jeffrey Infante, Malcolm Moore, Thomas Seay, Sergei A Tjulandin, Wen Wee Ma, Mansoor N Saleh,[...]. N Engl J Med 2013
5

Genomic analyses identify molecular subtypes of pancreatic cancer.
Peter Bailey, David K Chang, Katia Nones, Amber L Johns, Ann-Marie Patch, Marie-Claude Gingras, David K Miller, Angelika N Christ, Tim J C Bruxner, Michael C Quinn,[...]. Nature 2016
5

Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine.
Andrew J Aguirre, Jonathan A Nowak, Nicholas D Camarda, Richard A Moffitt, Arezou A Ghazani, Mehlika Hazar-Rethinam, Srivatsan Raghavan, Jaegil Kim, Lauren K Brais, Dorisanne Ragon,[...]. Cancer Discov 2018
130
5

Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval.
Peter C Fong, Timothy A Yap, David S Boss, Craig P Carden, Marja Mergui-Roelvink, Charlie Gourley, Jacques De Greve, Jan Lubinski, Susan Shanley, Christina Messiou,[...]. J Clin Oncol 2010
651
5

A requirement for PARP-1 for the assembly or stability of XRCC1 nuclear foci at sites of oxidative DNA damage.
Sherif F El-Khamisy, Mitsuko Masutani, Hiroshi Suzuki, Keith W Caldecott. Nucleic Acids Res 2003
455
5

Family-wide analysis of poly(ADP-ribose) polymerase activity.
Sejal Vyas, Ivan Matic, Lilen Uchima, Jenny Rood, Roko Zaja, Ronald T Hay, Ivan Ahel, Paul Chang. Nat Commun 2014
255
5

Serine ADP-Ribosylation Depends on HPF1.
Juan José Bonfiglio, Pietro Fontana, Qi Zhang, Thomas Colby, Ian Gibbs-Seymour, Ilian Atanassov, Edward Bartlett, Roko Zaja, Ivan Ahel, Ivan Matic. Mol Cell 2017
146
5

HPF1/C4orf27 Is a PARP-1-Interacting Protein that Regulates PARP-1 ADP-Ribosylation Activity.
Ian Gibbs-Seymour, Pietro Fontana, Johannes Gregor Matthias Rack, Ivan Ahel. Mol Cell 2016
122
5

Poly(ADP-ribose)-dependent regulation of DNA repair by the chromatin remodeling enzyme ALC1.
Dragana Ahel, Zuzana Horejsí, Nicola Wiechens, Sophie E Polo, Elisa Garcia-Wilson, Ivan Ahel, Helen Flynn, Mark Skehel, Stephen C West, Stephen P Jackson,[...]. Science 2009
391
5

Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer.
Neha Chopra, Holly Tovey, Alex Pearson, Ros Cutts, Christy Toms, Paula Proszek, Michael Hubank, Mitch Dowsett, Andrew Dodson, Frances Daley,[...]. Nat Commun 2020
47
10

Replication Gaps Underlie BRCA Deficiency and Therapy Response.
Nicholas J Panzarino, John J Krais, Ke Cong, Min Peng, Michelle Mosqueda, Sumeet U Nayak, Samuel M Bond, Jennifer A Calvo, Mihir B Doshi, Matt Bere,[...]. Cancer Res 2021
24
20

Pan-cancer landscape of homologous recombination deficiency.
Luan Nguyen, John W M Martens, Arne Van Hoeck, Edwin Cuppen. Nat Commun 2020
46
10

A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer.
Paz Polak, Jaegil Kim, Lior Z Braunstein, Rosa Karlic, Nicholas J Haradhavala, Grace Tiao, Daniel Rosebrock, Dimitri Livitz, Kirsten Kübler, Kent W Mouw,[...]. Nat Genet 2017
228
5

A Genetic Map of the Response to DNA Damage in Human Cells.
Michele Olivieri, Tiffany Cho, Alejandro Álvarez-Quilón, Kejiao Li, Matthew J Schellenberg, Michal Zimmermann, Nicole Hustedt, Silvia Emma Rossi, Salomé Adam, Henrique Melo,[...]. Cell 2020
90
5

Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial.
Noel Clarke, Pawel Wiechno, Boris Alekseev, Nuria Sala, Robert Jones, Ivo Kocak, Vincenzo Emanuele Chiuri, Jacek Jassem, Aude Fléchon, Charles Redfern,[...]. Lancet Oncol 2018
144
5

Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer.
M Catherine Pietanza, Saiama N Waqar, Lee M Krug, Afshin Dowlati, Christine L Hann, Alberto Chiappori, Taofeek K Owonikoko, Kaitlin M Woo, Robert J Cardnell, Junya Fujimoto,[...]. J Clin Oncol 2018
151
5

PRIMPOL-Mediated Adaptive Response Suppresses Replication Fork Reversal in BRCA-Deficient Cells.
Annabel Quinet, Stephanie Tirman, Jessica Jackson, Saša Šviković, Delphine Lemaçon, Denisse Carvajal-Maldonado, Daniel González-Acosta, Alexandre T Vessoni, Emily Cybulla, Matthew Wood,[...]. Mol Cell 2020
55
9

TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes.
Nadine M Tung, Mark E Robson, Steffen Ventz, Cesar A Santa-Maria, Rita Nanda, Paul K Marcom, Payal D Shah, Tarah J Ballinger, Eddy S Yang, Shaveta Vinayak,[...]. J Clin Oncol 2020
57
8

Overlapping roles for PARP1 and PARP2 in the recruitment of endogenous XRCC1 and PNKP into oxidized chromatin.
Hana Hanzlikova, William Gittens, Katerina Krejcikova, Zhihong Zeng, Keith W Caldecott. Nucleic Acids Res 2017
83
6

Analysis of PARP inhibitor toxicity by multidimensional fluorescence microscopy reveals mechanisms of sensitivity and resistance.
Jone Michelena, Aleksandra Lezaja, Federico Teloni, Thomas Schmid, Ralph Imhof, Matthias Altmeyer. Nat Commun 2018
43
11

Homologous recombination and the repair of DNA double-strand breaks.
William Douglass Wright, Shanaya Shital Shah, Wolf-Dietrich Heyer. J Biol Chem 2018
222
5

PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer.
Benjamin H Lok, Eric E Gardner, Valentina E Schneeberger, Andy Ni, Patrice Desmeules, Natasha Rekhtman, Elisa de Stanchina, Beverly A Teicher, Nadeem Riaz, Simon N Powell,[...]. Clin Cancer Res 2017
143
5

SLFN11 Blocks Stressed Replication Forks Independently of ATR.
Junko Murai, Sai-Wen Tang, Elisabetta Leo, Simone A Baechler, Christophe E Redon, Hongliang Zhang, Muthana Al Abo, Vinodh N Rajapakse, Eijiro Nakamura, Lisa M Miller Jenkins,[...]. Mol Cell 2018
100
5

Exploring and comparing adverse events between PARP inhibitors.
Christopher J LaFargue, Graziela Z Dal Molin, Anil K Sood, Robert L Coleman. Lancet Oncol 2019
106
5

Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer.
A G Waks, O Cohen, B Kochupurakkal, D Kim, C E Dunn, J Buendia Buendia, S Wander, K Helvie, M R Lloyd, L Marini,[...]. Ann Oncol 2020
41
12

Sequential Therapy with PARP and WEE1 Inhibitors Minimizes Toxicity while Maintaining Efficacy.
Yong Fang, Daniel J McGrail, Chaoyang Sun, Marilyne Labrie, Xiaohua Chen, Dong Zhang, Zhenlin Ju, Christopher P Vellano, Yiling Lu, Yongsheng Li,[...]. Cancer Cell 2019
72
5

Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer.
Triparna Sen, B Leticia Rodriguez, Limo Chen, Carminia M Della Corte, Naoto Morikawa, Junya Fujimoto, Sandra Cristea, Thuyen Nguyen, Lixia Diao, Lerong Li,[...]. Cancer Discov 2019
231
4

An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations.
Nicholas Pulliam, Fang Fang, Ali R Ozes, Jessica Tang, Adeoluwa Adewuyi, Harold Keer, John Lyons, Stephen B Baylin, Daniela Matei, Harikrishna Nakshatri,[...]. Clin Cancer Res 2018
49
8

The zinc-finger domains of PARP1 cooperate to recognize DNA strand breaks.
Ammar A E Ali, Gyula Timinszky, Raquel Arribas-Bosacoma, Marek Kozlowski, Paul O Hassa, Markus Hassler, Andreas G Ladurner, Laurence H Pearl, Antony W Oliver. Nat Struct Mol Biol 2012
142
4

ATM Mutations in Cancer: Therapeutic Implications.
Michael Choi, Thomas Kipps, Razelle Kurzrock. Mol Cancer Ther 2016
200
4

The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.
Victoria J Weston, Ceri E Oldreive, Anna Skowronska, David G Oscier, Guy Pratt, Martin J S Dyer, Graeme Smith, Judy E Powell, Zbigniew Rudzki, Pamela Kearns,[...]. Blood 2010
217
4

2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity.
Parker L Sulkowski, Christopher D Corso, Nathaniel D Robinson, Susan E Scanlon, Karin R Purshouse, Hanwen Bai, Yanfeng Liu, Ranjini K Sundaram, Denise C Hegan, Nathan R Fons,[...]. Sci Transl Med 2017
243
4

Structural Basis of Detection and Signaling of DNA Single-Strand Breaks by Human PARP-1.
Sebastian Eustermann, Wing-Fung Wu, Marie-France Langelier, Ji-Chun Yang, Laura E Easton, Amanda A Riccio, John M Pascal, David Neuhaus. Mol Cell 2015
139
4

Rad51 protects nascent DNA from Mre11-dependent degradation and promotes continuous DNA synthesis.
Yoshitami Hashimoto, Arnab Ray Chaudhuri, Massimo Lopes, Vincenzo Costanzo. Nat Struct Mol Biol 2010
323
4

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial.
M William Audeh, James Carmichael, Richard T Penson, Michael Friedlander, Bethan Powell, Katherine M Bell-McGuinn, Clare Scott, Jeffrey N Weitzel, Ana Oaknin, Niklas Loman,[...]. Lancet 2010
952
4

BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency.
Chaoyang Sun, Jun Yin, Yong Fang, Jian Chen, Kang Jin Jeong, Xiaohua Chen, Christopher P Vellano, Zhenlin Ju, Wei Zhao, Dong Zhang,[...]. Cancer Cell 2018
114
4

Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study.
Joyce F Liu, William T Barry, Michael Birrer, Jung-Min Lee, Ronald J Buckanovich, Gini F Fleming, Bj Rimel, Mary K Buss, Sreenivasa Nattam, Jean Hurteau,[...]. Lancet Oncol 2014
363
4

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors.
Patricia M LoRusso, Jing Li, Angelika Burger, Lance K Heilbrun, Edward A Sausville, Scott A Boerner, Daryn Smith, Mary Jo Pilat, Jie Zhang, Sara M Tolaney,[...]. Clin Cancer Res 2016
59
6


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.